COMMENTARIES
Inhaled selective β 2 -agonists are the most widely used treatment for the acute relief of asthma symptoms. In patients with asthma, these agents cause bronchodilation (improvement in lung mechanics) and bronchoprotection (reduced responsiveness to nonspecific contractile stimuli). These actions result from binding to the β 2 -adrenergic receptor (β 2 AR), a heptahelical receptor that couples predominantly to the stimulatory G protein, G s ( Figure 1a) . Once activated by receptor-ligand binding, the α subunit of G s activates adenylyl cyclase (AC), resulting in cAMP formation. cAMP phosphorylates protein kinase A (PKA), which phosphorylates multiple proteins, leading to reductions in intracellular calcium, smooth muscle relaxation, and bronchodilation.
It is possible to have too much of a good thing. Despite the ability of β-agonists to effect immediate reversal of airway obstruction, there has been continuing concern that regular use of these drugs may be associated with adverse outcomes. In some, but not all, studies, regularly scheduled use (e.g., multiple times per day, every day) of inhaled β-agonists has resulted in loss of asthma control, declines in morning peak flow, longer durations of asthma exacerbations, and rebound airway hyperresponsiveness (1) (2) (3) (4) (5) (6) . These adverse effects appear to be particularly important with β-agonists of high intrinsic efficacy, like fenoterol, and in patients with certain β 2 AR genotypes.
The common explanation for these observations is that the adverse effects of regular β-agonist therapy are related to desensitization of the β 2 AR (2, 3, 5, 7). The data reported by McGraw et al. in this issue of the JCI (8) suggest an alternative explanation, namely that persistent high-level activation of the β 2 AR leads to increased expression of phospholipase C-β (PLCβ) in airway smooth muscle. Since agonists such as acetylcholine, histamine, and leukotrienes that cause airway smooth muscle contraction do so by
In an unusual paradox, asthmatics who are chronically treated with bronchodilating β-agonists sometimes experience a worsening of their condition. A new study (see the related article beginning on page 619) describes one possible mechanism and reveals a potential new therapeutic target in the treatment of asthma. McGraw et al. (8) report one such event, induction of PLCβ, but it is possible that this is just the tip of the iceberg. Understanding the panoply of β 2 AR-mediated events in airway smooth muscle might lead to the design of new agonists that avoid negative effects of β 2 AR activation while enhancing events that lead to relaxation.
acting on receptors that couple to G q and activate PLCβ, chronic β-agonists might augment the effects of these bronchoconstrictors. How could this occur? PLCβ hydrolyzes phosphatidylinositol 4,5 biphosphate, resulting in inositol 1,4,5 trisphosphate (IP 3 ) production. IP 3 increases intracellular calcium, leading to activation of myosin light chain kinase, myosin phosphorylation, and consequent muscle contraction. If the observations of McGraw et al. are borne out, this mechanism could explain the adverse effects of chronic stimulation of the β 2 AR. However, before we embrace this hypothesis, which is based on data from mouse airways, it will be important to confirm the observations of McGraw et al. in human airway smooth muscle stimulated with β-agonists rather than by β 2 AR overexpression.
We think that there may be additional explanations for the bronchoconstrictor effects of chronic β 2 AR stimulation. For example, in some cell types the β 2 AR can couple to G i as well as G s (9) (10) (11) (12) . The switch from G s to G i coupling appears to be regulated by PKA phosphorylation of the β 2 AR (13). β 2 AR-induced G i activation leads to activation of the extracellular signal-regulated kinase (ERK) MAPKs (Figure 1b ) through a pathway dependent on the G i βγ subunits and activation of Ras (12) . β 2 AR activation also leads to G protein receptor kinase-induced (GRK-induced) phosphorylation of the β 2 AR, resulting in its interaction with β-arrestin. β-arrestin can serve as a scaffolding protein linking the β 2 AR to both the ERK and JNK MAPK pathways (9, 14) . To complicate the matter, G s -dependent formation of cAMP by β 2 AR activation can also inhibit ERK activation (10), apparently as a result of Raf-1 phosphorylation by PKA (15) . The ultimate effect of β 2 AR activation on ERK phosphorylation is likely to reflect a balance of these various events.
Although these pathways have been described in other cell types, none of these events has been examined in airway smooth muscle cells. Thus it is interesting to consider the potential functional implications of β-agonist-induced ERK activation in these cells. Persistent ERK activation is known to be required for mitogenesis in airway smooth muscle cells (16) . Activation of ERK is also required for the full expression by airway smooth muscle of the eosinophil chemotactic factors eotaxin and RANTES, as well as other chemokines (17) . β-agonists normally inhibit mitogenesis (18) and inhibit expression of eotaxin (19) in airway smooth muscle. However, there may be conditions in which this is not the case. For example, G s -to-G i switching could be exaggerated by inflammatory cytokines, which have been shown to increase G i expression (20). Inflammatory cytokines have also been shown to increase GRK expression in these cells (20). Increased GRK activation could be expected to enhance ERK activation through effects on β-arrestin binding to the β 2 AR. It is also possible that the balance of ERK-activating and ERKinhibiting effects of β 2 AR activation may be affected by β 2 AR desensitization under conditions of regular β-agonist use.
It is interesting to note that the adverse effects of regular β-agonist use can be observed even weeks after their withdrawal, at a time when β 2 AR desensitization should be resolved (2) . If regular use of β-agonists negatively impacts the balance of factors contributing to airway smooth muscle mitogenesis or airway remodeling in asthma, it could have long-term consequences. Importantly, studies of regular use of β-agonist have reported adverse effects only in subjects homozygous for the Arg16 variant of the β 2 AR (2, 3, 5) . The impact of β 2 AR polymorphisms on non-G s -mediated events such as ERK phosphorylation has not been examined in any cell type.
β-agonists are currently one of the most important forms of therapy for asthma. Little is known about non-G s -mediated effects of β 2 AR activation and other events that could negatively impact the function of airway smooth muscle in asthma. In this issue of the JCI, 20. Mak, J.C., Hisada, T., Salmon, M., Barnes, P.J., and Chung, K.F. (Figure 1) (8) . Genes that are bound by TR/RXR heterodimers, and potentially TR homodimers, are actively repressed in the absence of TH. The repression function is located in the C-terminal ligand-binding domain, which binds to the corepressor molecules nuclear receptor corepressor (N-CoR) and silencing mediator of retinoid and thyroid receptors (SMRT) (9) , which anchor large multiprotein complexes containing histone deacetylase (HDAC) activity and mediate ligand-independent repression. TH binding induces a conformational change that destabilizes corepressor binding and that favors binding of transcriptional coactiva-
